ÌÇÐÄÊÓÆµ

Xi Chen

Chen

Xi Chen, Ph.D.

Cullen Duncan McAshan Endowed Chair in Cancer Research

Positions

Cullen Duncan McAshan Endowed Chair in Cancer Research
Molecular and Cellular Biology
ÌÇÐÄÊÓÆµ of Medicine
Houston, Texas, United States
Associate Professor and CPRIT Scholar in Cancer Research
Molecular and Cellular Biology
ÌÇÐÄÊÓÆµ of Medicine
Houston, Texas, United States
Member
Dan L Duncan Comprehensive Cancer Center
ÌÇÐÄÊÓÆµ of Medicine
Houston, Texas, United States

Education

Postdoctoral Fellowship at Laurie Glimcher Lab, Weill Cornell Medical College
01/2015 - New York, New York, United States
Postdoctoral Fellowship at Laurie Glimcher Lab, Harvard School of Public Health/Harvard Medical School
09/2012 - Boston, Massachusetts, United States
PhD from Huck Hui Ng Lab, Genome Institute of Singapore, A*STAR/National University of Singapore
02/2009 - Singapore, Singapore

Honors & Awards

CPRIT Scholar in Cancer Research
Cancer Prevention Research Institute of Texas (CPRIT) (03/2015 - 02/2019)
Leukemia & Lymphoma Society Career Development Fellow Award
Leukemia & Lymphoma Society (07/2009 - 07/2012)
NIH MERIT Award for Early Stage Investigator
NCI/NIH (07/2018 - 06/2023)

Professional Interests

  • ER protein quality control; Tumor Microenvironment; Cancer Immunology; Therapy resistance; Stem Cell Maintenance; Unfolded Protein Response; Endoplasmic Reticulum-Associated Degradation;

Professional Statement

The Chen laboratory studies how cancer and its immune microenvironment sense and respond to stresses and therapeutic insults to evade immune surveillance and develop drug resistance. We specialize in ER stress, Unfolded Protein Response (UPR), immunology, cancer biology, biochemistry, transgenic and preclinical animal models. Our research aims to elucidate the significance and mechanisms of stress responses in therapy resistance and anti-tumor immunity, and develop mechanism-based novel therapies to overcome therapy resistance and transform cancer to a manageable chronic disease (Nat Rev Cancer, 2021). Our study published in JCI revealed a critical role of the IRE1a/XBP1 branch of the UPR in mediating chemotherapy resistance and led to the first-in-human clinical trial of IRE1a RNase inhibitor. Our efforts in understanding proteostasis regulation revealed the direct cross-talk between oncogenic signaling and the protein quality control machinery and uncovered the mechanisms that account for the proteostasis rewiring in response to KRAS inhibition, allowing the drug-resistant cells to escape oncogenic KRAS addiction and gain resistance (Science, 2023). Another research area of the Chen laboratory focuses on ER Associated Degradation (ERAD). We recently discovered the crosstalk between ERAD complex and UPR in maintaining proteostasis and niche interactions (Nat Cell Biol, 2020, eLife, 2021).

Selected Publications

  • Lv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, Pataer A, Lu D, ....Chen Y, Yao W, Chang EC, Catic A, Lin X, Miles G, Huang P, Sun Z, Burt B, Wang H, Wang J, Yao QC, Zhang B, Roth JA, O'Malley BW, Ellis MJ, Rimawi MF, Ying H, Chen X.. " " Science. 2023 Sep 8; 381(6662)
    Pubmed PMID: .
  • Xu L, Liu X, Peng F, Zhang W, Zheng L, Ding Y, Gu T, Lv K, Wang J, Ortinau L, Hu T, Shi X, Shi G, Shang G, Sun S, Iwawaki T, Ji Y, Li W, Rosen JM, Zhang XH, Park D, Adoro S, Catic A, Tong W, Qi L, Nakada D, Chen X. " " Nat Cell Biol. 2020 Oct 22; 22 (10) : 1162-1169.
    Pubmed PMID: .
  • Zhao N, Cao J ,Xu LY, Tang QZ, Dobrolecki L, Lyu XD, Talukdar M, Lu Y, Wang XR, Wang YF, Liu X, Bu W, Sun Z, Ying HQ, Lin X, Feng XH, Hartig S, Li F, Shen HF, Chen YW, Han L, Zeng QP, Patterson J, Putluri N, Sicheri F, Rosen J, Lewis MT, Chen X. " " J Clin Invest. 2018 ; 128 (4) : 1283-1299.
    Pubmed PMID: .
  • Chen X#, Cubillos-Ruiz JR#.. " " Nat Rev Cancer. 2020 Nov 19; (#: Corresponding Author)
    Pubmed PMID: .

to edit your profile